Form 4: CytomX CEO Granted 210K RSUs, 980K Stock Options

CytomX Therapeutics CEO Sean A. McCarthy was granted 210,000 restricted stock units and 980,000 stock options on February 2, 2026.

Summary

• CEO Sean A. McCarthy of CytomX Therapeutics, Inc. was granted 210,000 Restricted Stock Units (RSUs) on February 2, 2026.
• These RSUs will vest in three annual installments, with the first third vesting on March 15, 2027, contingent on continued service.
• McCarthy also received a grant of 980,000 stock options with an exercise price of $6.09 per share on February 2, 2026.
• The stock options vest monthly over four years, with 1/48th vesting on each monthly anniversary from February 2, 2026, subject to continued service.
• Following these transactions, McCarthy directly beneficially owns 1,197,891 shares of common stock (including 698,750 RSUs) and 980,000 stock options.
• Additionally, 93,158 shares are indirectly beneficially owned through the Sean A. McCarthy 2018 Trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it represents a significant equity grant to the CEO, aligning his interests with long-term shareholder value, which is generally well-received by the market.

Positives

• The CEO's acquisition of 210,000 Restricted Stock Units (RSUs) and 980,000 stock options indicates a strong alignment of management's interests with long-term shareholder value.
• The vesting schedules for both the RSUs (annual over three years) and stock options (monthly over four years) incentivize the CEO's continued service and performance.

Negatives

• No negative transactions (e.g., sales) were reported in this filing.

Future Outlook

The vesting schedules for the granted Restricted Stock Units and stock options extend several years into the future, indicating an expectation of continued service from the CEO and a long-term focus on company performance.

Industry Context

StockSavvy.ai notes that executive compensation packages, particularly those involving equity grants like RSUs and stock options, are standard practice in the biotechnology and pharmaceutical sectors. These grants are designed to align executive incentives with long-term company performance and shareholder returns, which is crucial in an industry characterized by long development cycles and significant R&D investments.

Comparison to Industry Standards

• The grant of a substantial number of RSUs and stock options to a CEO is a common compensation strategy in the biotech industry, comparable to practices at companies like Amgen or Gilead Sciences, where executive compensation often includes significant equity components tied to performance and tenure.
• The vesting schedules (3-year for RSUs, 4-year for options) are typical for executive equity grants, aiming to retain key talent and incentivize sustained performance, similar to structures seen in compensation plans at peer companies within the small to mid-cap biotech space.

Stakeholder Impact

• Shareholders: The grants align the CEO's incentives with long-term shareholder value, potentially leading to improved company performance.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Vesting of 1/3rd of RSUs on March 15, 2027, and annually thereafter.
• Monthly vesting of stock options over four years from February 2, 2026.

Key Dates

Recommendation

While the significant equity grants to the CEO are a positive sign of alignment and confidence, a Form 4 filing primarily reports insider transactions and does not provide comprehensive financial or operational updates to warrant a 'buy' recommendation. Investors should 'hold' and await broader company performance indicators or strategic announcements for a more complete investment picture.

Keywords

CytomX Therapeutics, CTMX, Sean A. McCarthy, CEO, Restricted Stock Units, RSUs, Stock Options, Insider Grant, Executive Compensation, Beneficial Ownership